| NCT06653842 | A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations | RECRUITING | PHASE2 | 2024-12-20 | 2026-03 | 2025-12 |
| NCT06239480 | SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | RECRUITING | PHASE3 | 2024-07-31 | 2026-07 | 2026-01 |
| NCT05643872 | A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita | RECRUITING | PHASE3 | 2022-11-15 | 2023-11 | 2023-10 |
| NCT05050149 | Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations | COMPLETED | PHASE2 | 2022-01-13 | 2022-12-15 | 2022-11-15 |
| NCT05180708 | A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita | COMPLETED | PHASE3 | 2021-11-29 | 2023-06-30 | 2023-06-30 |
| NCT04893486 | CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome | COMPLETED | PHASE2 | 2021-05-06 | 2023-03-13 | 2023-03-13 |
| NCT04520750 | VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita | COMPLETED | PHASE3 | 2020-09-01 | 2022-12-15 | 2021-06-30 |
| NCT03920228 | Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita | COMPLETED | PHASE2, PHASE3 | 2019-04-01 | 2020-10-19 | 2020-09-19 |